USP14 inhibitor IU1 significantly increases CD36 ubiquitination and stabilizes CD36 protein by removing the polyubiquitin chains, decreasing foam cell formation by downregulating CD36-mediated lipid uptake, and providing a potential therapeutic target for atherosclerosis [75]. Here, USP14 is linked to atherosclerosis.